# Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

> **NCT06227325** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 27 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** RC48 combined with Sintilimab and XELOX

## Key facts

- **NCT ID:** NCT06227325
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2024-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06227325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06227325, "Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06227325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*